Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295002 | 0.86 | GPR119 (0.71) | GPR119MMP13 | |
| SCHEMBL2216383 | 0.85 | GPR119 (0.45) | GPR119MMP2MMP3MMP9MMP8 | |
| SCHEMBL12434644 | 0.85 | GPR119 (0.45) | GPR119MMP2MMP3MMP9MMP8 | |
| SCHEMBL2216375 | 0.85 | GPR119 (0.45) | GPR119MMP2MMP3MMP9MMP8 | |
| SCHEMBL12106817 | 0.85 | GPR119 (0.44) | GPR119 | |
| SCHEMBL2433621 | 0.83 | GPR119 (0.56) | GPR119 | |
| SCHEMBL1840318 | 0.82 | USP30 (0.42) | GPR119 | |
| SCHEMBL1295590 | 0.80 | GPR119 (0.55) | GPR119LMNASMN1; SMN2 | |
| SCHEMBL1841610 | 0.80 | ADAM17 (0.42) | GPR119MMP2MMP3MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL1296274 | 0.79 | ADAM17 (0.41) | GPR119MMP2MMP3MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377863-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2114933-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048632-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885MMP2 3281/4885MMP3 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.